{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:38:01Z","timestamp":1772991481386,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,16]],"date-time":"2027-01-16T00:00:00Z","timestamp":1800057600000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2025.09.020","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:36:01Z","timestamp":1757781361000},"page":"80.e1-80.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-9393","authenticated-orcid":false,"given":"Rachel B.","family":"Salit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nellie","family":"Ratsamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anise","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jtct.2025.09.020_bib0001","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.jtct.2025.09.020_bib0002","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.jtct.2025.09.020_bib0004","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.jtct.2025.09.020_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.jtct.2025.09.020_bib0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0007","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"issue":"34","key":"10.1016\/j.jtct.2025.09.020_bib0008","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.jtct.2025.09.020_bib0009","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.jtct.2025.09.020_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J Hematol Oncol."},{"issue":"9","key":"10.1016\/j.jtct.2025.09.020_bib0011","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.jtct.2025.09.020_bib0012","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.jtct.2025.09.020_bib0013","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"33","key":"10.1016\/j.jtct.2025.09.020_bib0015","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.jtct.2025.09.020_bib0016","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.jtct.2025.09.020_bib0017","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.jtct.2025.09.020_bib0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.jtct.2025.09.020_bib0019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.jtct.2025.09.020_bib0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.jtct.2025.09.020_bib0021","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.jtct.2025.09.020_bib0022","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"3","key":"10.1016\/j.jtct.2025.09.020_bib0023","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.jtct.2025.09.020_bib0024","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41409-023-02146-6","article-title":"Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study","volume":"59","author":"Maze","year":"2024","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.jtct.2025.09.020_bib0026","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0027","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.jtct.2025.09.020_bib0028","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.09.020_bib0029","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/busulfan conditioning-based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.jtct.2025.09.020_bib0030","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.jtct.2025.09.020_bib0031","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.jtct.2025.09.020_bib0032","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kr\u00f6ger","year":"2005","journal-title":"Br J Haematol."},{"issue":"26","key":"10.1016\/j.jtct.2025.09.020_bib0033","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.jtct.2025.09.020_bib0034","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbmt.2015.09.028","article-title":"Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors","volume":"22","author":"Bregante","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"10.1016\/j.jtct.2025.09.020_bib0036","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"10.1016\/j.jtct.2025.09.020_bib0037","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41409-022-01649-y","article-title":"The role of JAK inhibitors in hematopoietic cell transplantation","volume":"57","author":"Salit","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.jtct.2025.09.020_bib0038","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.jtct.2025.09.020_bib0039","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2018.09.033","article-title":"Patient perspectives regarding allogeneic bone marrow transplantation in myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.jtct.2025.09.020_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14740\/jh914","article-title":"Validation of a modified version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score","volume":"10","author":"Langlais","year":"2021","journal-title":"J Hematol."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:56:22Z","timestamp":1772974582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666636725014460"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}